|
Clinical Trial of Leuprolide Acetate for the Treatment of PMS Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Clinical Trial of Leuprolide Acetate for the Treatment of PMS conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Clinical Trial of Leuprolide Acetate for the Treatment of PMS Clinical research trials and Clinical Trial of Leuprolide Acetate for the Treatment of PMS healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Clinical Trial of Leuprolide Acetate for the Treatment of PMS. Clinical Trial of Leuprolide Acetate for the Treatment of PMS Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Clinical Trial of Leuprolide Acetate for the Treatment of PMS clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Clinical Trial of Leuprolide Acetate for the Treatment of PMS condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Clinical Trial of Leuprolide Acetate for the Treatment of PMS  Clinical Trial of Leuprolide Acetate for the Treatment of PMS
Clinical Trial of Leuprolide Acetate for the Treatment of PMS
For Condition: Depressive Disorder,Mood Disorder
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to examine the influence of estrogen and progesterone on mood and behavior in women with premenstrual syndrome. Previously this study has demonstrated leuprolide acetate (Lupron® (Registered Trademark)) to be an effective treatment for PMS. The current purpose of this study is to evaluate how low levels of estrogen and progesterone (that occur during treatment with leuprolide acetate) compare to menstrual cycle levels of estrogen and progesterone (given during individual months of hormone add-back) on a variety of physiologic measures (brain imaging, stress testing, etc.) in women with PMS. PMS is a condition characterized by changes in mood and behavior that occur during the second phase of the normal menstrual cycle (luteal phase). This study will investigate possible hormonal causes of PMS by temporarily stopping the menstrual cycle with leuprolide acetate and then giving, in sequence, the menstrual cycle hormones progesterone and estrogen. The results of these hormonal studies will be compared between women with PMS and healthy volunteers without PMS (see also protocol 92-M-0174). At study entry, participants will undergo a physical examination. Blood, urine, and pregnancy tests will be performed. Cognitive functioning and stress response will be evaluated during the study along with brain imaging and genetic studies.
Details: This protocol is designed to accompany Clinical Protocol # 81-M-0126, The Phenomenology and Biophysiology of Menstrually-Related Mood and Behavioral Disorders. Its original purposes were as follows: 1) to evaluate the efficacy of the gonadotropin releasing hormone (GnRH) agonist depot leuprolide acetate (Lupron) in the treatment of menstrually-related mood disorders (MRMD) by determining whether mood and behavioral symptoms are eliminated when the cyclic secretion of both gonadotropic hormones and gonadal steroids is suppressed, and 2) to determine the possible relevance of gonadal steroids to affective state by sequentially replacing estradiol and progesterone during continued GnRH suppression in those patients whose premenstrual symptoms remit following administration of the GnRH agonist. We observed that GnRH agonist induced ovarian suppression was an effective treatment compared to placebo in women with MRMD. Additionally, women with MRMD but not asymptomatic controls (participating in companion protocol 92-M-0174) experienced a recurrence of mood and behavioral symptoms when either estradiol or progesterone (but not placebo) was added back. These data suggest that women with MRMD have a differential sensitivity to the mood destabilizing effects of gonadal steroids. Having established that women with MRMD show a differential behavioral response to estrogen and progesterone, we now hope to identify the underlying mechanisms and physiologic concomitants of the differential behavioral sensitivity by performing studies (described in companion protocols) under the three hormonal conditions created by this protocol, and comparing results obtained with those seen in normal controls (Protocol #92-M-0174). Planned studies include the following: cognitive testing, HPA axis function evaluation with social stress testing, brain imaging (3D PET, FMRI, MRS) and genetic studies.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Female
Protocol Entry Criteria: INCLUSION CRITERIA: Criteria for Patient Selection The subjects of this study will be women who meet the criteria for MRMD as described in Protocol No. 81-M-0126, 'The Phenomenology and Biophysiology of Menstrually-related Mood and Behavioral Disorders.' In brief, these criteria include: 1) history within the last two years of at least six months with menstrually-related mood or behavioral disturbances of at least moderate severity--i.e., disturbances that are distinct in appearance and associated with a notable degree of subjective distress; 2) symptoms should have a sudden onset and offset; 3) age 18-40; 4) not pregnant and in good health; 5) medication free. All patients participating in this protocol will have already participated in Protocol No. 81-M-0126 and will have a prospectively confirmed and predictable relationship between their mood disorder and the premenstrual phase of the menstrual cycle, i.e., a 30% change in severity of symptoms self rating scales, relative to the range of the scale employed, during the seven days premenstrually compared with the seven days post-menstrually in two out of three months of study. The Schedule for Affective Disorders and Schizophrenia will be administered to all patients prior to study entry. Any patient with a current axis I psychiatric diagnosis will be excluded from participating in this protocol. Prior to treatment, a complete physical and neurological examination will have been performed and the following routine laboratory data obtained: A. Blood Complete blood count; thyroid function tests; cortisol; renal function tests, such as BUN and creatinine; electrolytes; glucose; liver function tests. B. Urine Routine urinalysis; urine pregnancy test. GnRH agonist will not be administered to any subject with significant clinical or laboratory abnormalities. EXCLUSION CRITERIA: Results of Pap smear performed within one year of the onset of treatment will be obtained. Subjects taking birth control pills will be excluded from the study. Subjects taking diuretics, prostaglandin inhibitors, or pyridoxine (putative treatments for MRMD) will similarly be excluded from the study, as will patients taking psychotropic agents (e.g., lithium carbonate, tricyclic antidepressants). All subjects will be required to use non-hormonal forms of birth control (e.g. barrier methods) to avoid pregnancy during this study.
Total Enrollment: 100
Location and Contact Information:
National Institute of Mental Health (NIMH) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Linda Clair 3014969576
Additional Information:
Study ID Numbers: 900088; 90-M-0088
Study Start Date: March 9, 1990
Record last reviewed: February 27, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001259
Other Depressive Disorder Studies:
1. Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression
2. Clinical Trial of Leuprolide Acetate for the Treatment of PMS
3. Effects of Sex Hormones on Circadian Rhythm in Men and Women
4. The Effect of GnRH on Pitutitary Hormones in Menstrual-Cycle Mood Related Disorders
5. Perimenopause-Related Mood and Behavioral Disorders
Related Studies:
Other Depressive Disorder Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Clinical Trial of Leuprolide Acetate for the Treatment of PMS
|
|
|
|
|
|
|
|
